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Abstract: 
The last decade was taken by storm when the existence of a class of small (~22nt long) non – coding RNA species, known as microRNAs (miRNAs) came into 
light. MicroRNAs are one of the most abundant groups of regulatory genes in multicellular organisms and play fundamental roles in many cellular processes. 
Among these, miRNAs have been shown to prevent cell division and drive terminal differentiation, thus playing a causal role in the generation or maintenance of 
cancerous tumours. The unique expression profiles of different miRNAs in various types and stages of cancer suggest their performance as novel biomarkers. This 
discussion focuses on miRNAs implicated in cancer-associated events and strives to re-establish their sequential features which may classify them to be oncogenic. 
 
 
Keywords: microRNA, oncogene, sequence trademarks, purines 
 
 
 
 
Background: 
MicroRNAs (miRNAs) are RNA molecules, on average only 22 nucleotides, 
which act as post-transcriptional regulators by binding to complementary 
sequences on target messenger RNA transcripts. First discovered while 
studying mutations that changed the timing of developmental events in 
Caenorhabditis elegans  [1], they have now been identified in a variety of 
organisms  [2]  and can be found both in the plant and animal kingdoms. 
MicroRNAs are transcribed as parts of longer molecules (~ several kilobases) 
that are processed in the nucleus and form hairpin RNAs of 70–100 nt with the 
help of Drosha, the double-stranded RNA-specific ribonuclease [3, 4]. These 
hairpins are then transported to the cytoplasm, via an exportin 5-dependent 
mechanism, where they act as substrates for a second double-strand specific 
ribonuclease called Dicer [3, 5]. The single-stranded miRNA binds mostly to 
the 3’ Untranslated Region (UTR) of the specific messenger RNA. Initial 
estimates put the number of microRNA genes in the mammalian genome in the 
range of 200 to 1000 (׽1%–3% of known genes are represented by 
microRNAs). However, to this day, the number of microRNAs, including those 
electronically cloned, is over 1000 and still growing [6-8]. The majority of 
microRNAs (70%) are located in introns and/or exons, and approximately 30% 
are located in intergenic regions [9]. Analysis of the genomic location of 
human microRNA genes suggested that 50% of microRNA genes are located in 
cancer-associated genomic regions or in fragile sites, on chromosomes which 
are frequently deleted, amplified or rearranged in case of cancer development 
[10-12]. Altered expression pattern (over- or under-expression) of specific 
miRNAs has also been reported in tissues derived from various tumours [13, 
14]. Changes in miRNA expression patterns have also been identified in 
abnormal cell proliferation, which is a hallmark of human cancers. The role of 
let-7 in lung cancer development, miR – 145 in breast cancer tissues, and the 
28 different miRNAs in colonic adenocarcinoma, can all be cited as instances 
[14]. Some miRNAs have an increased expression in tumors (may be 
considered as oncogenes), others can also have decreased expression in 
cancerous cells (tumor suppressor genes). The oncogenic miRNAs are known 
as oncomirs and promote tumor development by negatively inhibiting tumor 
suppressor genes and/or genes that control cell differentiation or apoptosis. The 
present study was aimed at having a closer look into the sequential trademarks 
that may signify a miRNA to associate with cancer. Although there have been 
studies on prediction of oncogene regulation by miRNAs and other validation 
studies  [12, 15, 16], this discussion and review focuses solely on the 
identification of sequential distinction present in the human oncogenically – 
involved miRNAs.  
 
Approach and Findings: 
A database of oncogenically involved miRNAs (oncomirs) was constructed 
using the entries listed in the methods of Koscianski et al. (2007) [12]. These 
miRNAs were selected from Homo sapiens sequences in the "miRNA 
Registry" Release 7.1 [17]. Koscianski et al. (2007) had listed these entries 
after scanning and validation against possible oncogenic sequences derived 
from the human 3’UTR database. We further culled these sequences using the 
identity criterion and non-redundant sequences were thus collected. The 
resulting sequences were sorted under two different categories, viz., hsa 
miRNA and hsa let. Thus, a total of 135 miRNAs could be sorted into two 
subgroups of 122 (hsa miRNA) and 13 (hsa let). While the longest sequence 
thus encountered was 24 for a hsa miRNA entry, the shortest one was of 18 
nucleotides for a hsa miRNA. Since microRNAs have very short sequences, 
and sequence similarity is very high in miRNA families, we checked the 
rejected substitution score by using GERP conservation (miReval). Only three 
of the miRNA entries showed significant conservation – of which two were 
from hsa miRNA and one from hsa let. Hence, the final database was narrowed 
down to 132 miRNAs (120 hsa miRNA and 12 hsa let).  
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Figure 1: Plot depicting the sequence similarity of has miR and hsa let 
miRNAs against the frequency of their occurrences. 
 
The key software used for this analysis was MATLAB. Multiple sequence 
alignment of the sequences was done using ‘multialign’ function in MATLAB 
with ‘ExistingGapAdjust’ option. It helps to control automatic adjustment 
based on existing gaps by introducing hyphens in between sequences so that 
there is maximum match at positions of sequences. From the resulting multiple 
sequence alignment, sequence trademarks and specific attributes were searched 
for. Finally the percentage match at all the positions in the sequences was 
calculated. A plot of the percentage sequence similarities versus the frequency 
in numbers (Figure 1) shows that the two classes of miRNAs more-or-less 
exhibit some sequence similarity but are not exactly so. While most of the hsa 
let family miRNAs have a very high percentage similarity (8 out of 12), the hsa 
miR family are only moderately similar in sequence with the biggest peak in 
the 30% similarity range. 
What discriminates an oncogene-associated miRNA? 
From the available results, some sequential features in miRNAs are evident. 
The first remarkable feature is the rarity of Cytosines among the four bases. On 
the contrary, Uracil seems to be the nucleotide of choice. In general, we could 
conclude that purines occur more frequently than pyrimidines in both families 
of oncogenic microRNAs. Considering the flexibility of RNA structure in 
general, the abundance of the bulkier purines is something which needs further 
investigation. Considering sequence similarities in the more similar hsa let 
family, it was found that a “gaugau” motif was common to all oncomirs of that 
family. In the more diverged hsa miRNA family, the common motif was 
altered at the second base to be represented as “ggu-ggu”. To this effect, we 
concluded that human oncomirs can be identified by the presence of a sequence 
trademark of having a ‘gg(/a)u-gg(/a)u motif. The available result could be 
used for further identification and validation of oncomirs, and the authors are in 
the process of developing an algorithm to that effect, based on the sequence 
trademarks. 
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